IASO BioTherapeutics’ Equecabtagene Autoleucel Injection has proven both effective and safe in treating progressive multiple sclerosis (PMS) — one of medicine’s most complex challenges.

Founded in 2017, IASO BioTherapeutics specializes in the research, development, and commercialization of innovative cell therapies. Earlier this year, the Hong Kong Department of Health officially accepted its new drug application for Iquilunsai — marking the first-ever approval of a domestically developed CAR-T therapy for review in Hong Kong.
The product has also been submitted for approval in Macau, Singapore, Saudi Arabia, and South Korea, underscoring its global footprint.

From hematologic malignancies to autoimmune diseases, IASO BioTherapeutics is reshaping the treatment landscape for some of the world’s toughest medical challenges, with Cell’s recognition reaffirming Nanjing’s global standing in cell therapy innovation.